Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 14, 2015, 34 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.01 to $3,796,435.44.

Highlighted Stocks Traded by Insiders:

Omnicell (OMCL) - FREE Research Report

Petersmeyer Gary S, who is Director at Omnicell, sold 670 shares at $36.08 on April 14, 2015. Following this transaction, the Director owned 16,355 shares meaning that the stake was reduced by 3.94% with the 670-share transaction.

The shares most recently traded at $35.90, down $0.18, or 0.5% since the insider transaction. Historical insider transactions for Omnicell go as follows:

  • 4-Week # shares sold: 670
  • 12-Week # shares sold: 1,340
  • 24-Week # shares sold: 12,872

The average volume for Omnicell has been 218,100 shares per day over the past 30 days. Omnicell has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 8.64% year-to-date as of the close of trading on Tuesday.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates in two segments, Automation and Analytics, and Medication Adherence. The company has a P/E ratio of 43.5. Currently, there are 3 analysts who rate Omnicell a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMCL - FREE

TheStreet Quant Ratings

rates Omnicell as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Scroll to Continue

TheStreet Recommends

Omnicell Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Albany Molecular Research (AMRI) - FREE Research Report

D Ambra Constance M, who is 10% Owner at Albany Molecular Research, sold 20,000 shares at $18.50 on April 14, 2015. Following this transaction, the 10% Owner owned 2.5 million shares meaning that the stake was reduced by 0.81% with the 20,000-share transaction.

D Ambra Thomas E Phd, who is Chairman, Board of Directors at Albany Molecular Research, sold 20,000 shares at $18.50 on April 14, 2015. Following this transaction, the Chairman, Board of Directors owned 2.6 million shares meaning that the stake was reduced by 0.76% with the 20,000-share transaction.

The shares most recently traded at $18.59, up $0.09, or 0.48% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 3,500
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 86,285
  • 24-Week # shares bought: 60,000
  • 24-Week # shares sold: 206,285

The average volume for Albany Molecular Research has been 429,000 shares per day over the past 30 days. Albany Molecular Research has a market cap of $611.7 million and is part of the health care sector and drugs industry. Shares are up 13.45% year-to-date as of the close of trading on Tuesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Currently, there are 2 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings

rates Albany Molecular Research as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

Albany Molecular Research Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

IPG Photonics (IPGP) - FREE Research Report

Gapontsev Valentin P, who is CEO & Chairman of the Board at IPG Photonics, sold 500 shares at $100.06 on April 14, 2015. Following this transaction, the CEO & Chairman of the Board owned 300,431 shares meaning that the stake was reduced by 0.17% with the 500-share transaction.

The shares most recently traded at $97.39, down $2.67, or 2.74% since the insider transaction. Historical insider transactions for IPG Photonics go as follows:

  • 4-Week # shares sold: 23,075
  • 12-Week # shares sold: 97,485
  • 24-Week # shares sold: 352,801

The average volume for IPG Photonics has been 450,600 shares per day over the past 30 days. IPG Photonics has a market cap of $5.2 billion and is part of the technology sector and electronics industry. Shares are up 29.12% year-to-date as of the close of trading on Tuesday.

IPG Photonics Corporation develops and manufactures a range of high-performance fiber lasers, fiber amplifiers, and diode lasers used in various applications, primarily in materials processing worldwide. The company has a P/E ratio of 26.2. Currently, there are 6 analysts who rate IPG Photonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPGP - FREE

TheStreet Quant Ratings

rates IPG Photonics as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

IPG Photonics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null